Elmar Detering

Bayer HealthCare, Leverkusen, North Rhine-Westphalia, Germany

Are you Elmar Detering?

Claim your profile

Publications (4)6.34 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The 2013 Aspirin Foundation Conference covered a range of topics from clinical and medical history, epidemiology, health economics, and the current uses of aspirin in general practice and in the treatment and prevention of cancer. The use of aspirin as primary prevention in people at risk of atherosclerotic events is now well known, but its use as a preventative agent in some cancer types is still under discussion, and data on colorectal and lung cancer were presented at this meeting. The potential use of aspirin in preventing vascular disease in HIV patients was also discussed. The cost effectiveness of aspirin as a primary prevention strategy was discussed for the first time in this series of meetings.
    ecancermedicalscience 01/2014; 8(1):388. DOI:10.3332/ecancer.2014.388 · 1.20 Impact Factor
  • Andrew T. Chan · Elmar Detering ·

  • Andrew T Chan · Elmar Detering ·
    [Show abstract] [Hide abstract]
    ABSTRACT: There have been a number of promising recent developments in the prevention of colorectal cancer. This book examines in detail important aspects of the current status of and future prospects for chemoprevention of colorectal tumors, particularly using anti-inflammatory drugs. Research into the mechanisms that lead from early colorectal adenoma to colorectal cancer is discussed. The role and modes of action of available anti-inflammatory drugs, such as aspirin, celecoxib, and sulindac are described and recent data from trials of aspirin are reviewed. In addition, the possible impact of nutritional agents with anti-inflammatory properties is considered, and strategies applicable in those with a high level of genetic risk are evaluated. An important feature of the book is its interdisciplinary perspective, offering highly relevant information for gastroenterologists, internists, general practitioners, oncologists, colorectal and gastroenterological surgeons, and public health practitioners.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progr├Ęs dans les recherches sur le cancer 08/2012; 191:1-5. DOI:10.1007/978-3-642-30331-9_1
  • Doran Avivi · Menachem Moshkowitz · Elmar Detering · Nadir Arber ·
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Colorectal cancer (CRC) is a prevalent disease that is associated with considerable morbidity and mortality. The progression of normal mucosa through adenomatous polyps to overt cancer can span for 10 - 15 years, making early detection, as well as the use of chemopreventive agents such as aspirin, an attractive option. The effects of aspirin in reducing CRC incidence and mortality have consistently been demonstrated in a number of studies. However, a greater understanding of how aspirin exerts its anti-cancer effects is warranted. AREAS COVERED: The aim of this non-systematic review, which was developed using published randomized and epidemiological studies, as well as key references known to the authors, was to consider the role of aspirin in CRC prevention. Areas covered include the effects of aspirin on cardiovascular disease, CRC and colorectal adenoma (CRA) prevention, mode of action of aspirin and the benefit-to-risk of aspirin in disease prevention. EXPERT OPINION: Incorporating CRC and CRA benefits into coronary heart disease (CHD) risk scores would be particularly useful for determining the benefit-to-risk ratio for aspirin use in borderline cases. For instance, patients with an annual CHD risk around 0.7 - 1.4%, but with a high risk of colorectal neoplasm may benefit from aspirin. The strong association between CRC and age may also be useful for re-examining the benefit-to-risk ratio for aspirin use in older patients. However, it has to be noted that a cancer prevention indication for aspirin is not approved regulatory-wise anywhere.
    Expert Opinion on Therapeutic Targets 03/2012; 16 Suppl 1(S1):S51-62. DOI:10.1517/14728222.2011.647810 · 5.14 Impact Factor